What new treatments for Hairy Cell Leukemia are being developed in 2026

New and Emerging Treatments for Hairy Cell Leukemia in 2026

Based on the most current NCCN Guidelines (Version 1.2026, updated August 2025), here's what's happening with hairy cell leukemia (HCL) treatment development:

Recently Approved/Emerging Options

1. BRAF Inhibitor Combinations (Newer Approaches) According to NCCN Guidelines, dabrafenib plus trametinib represents an important newer option for patients with BRAF V600E-positive HCL, particularly in relapsed/refractory settings. This combination targets the specific genetic mutation found in most classical HCL cases. The guidelines note that BRAF inhibitors are "highly effective in patients with BRAF V600E-positive HCL, particularly in relapsed/refractory settings or when standard therapies are unsuitable."

2. BCL2 Inhibitors (Venetoclax) Venetoclax (with or without rituximab) has emerged as an option for patients with disease resistant to other treatments. This represents a shift toward targeting the proteins that help cancer cells survive.

3. BTK Inhibitors

• Zanubrutinib is now recognized in the guidelines specifically "for patients with disease resistant to BRAF inhibitor therapy"
• Ibrutinib continues to be studied for both classic and variant HCL

4. Anti-CD20 Monoclonal Antibodies Obinutuzumab has been added to the 2026 NCCN Guidelines as a newer option for relapsed/refractory disease, offering an alternative for patients who may not tolerate rituximab.

What Makes These "New"?

The 2026 guideline updates specifically highlight:

• Expanded use of obinutuzumab as an alternative anti-CD20 therapy
• Recognition that patients experiencing severe reactions to rituximab can safely switch to obinutuzumab
• Continued refinement of BRAF inhibitor combinations for better response rates

The Clinical Reasoning Behind These Developments

Doctors are moving toward personalized approaches based on:

• BRAF V600E mutation status (present in ~80% of classical HCL)
• Treatment history (what worked before, how long remission lasted)
• Patient tolerance (ability to handle side effects)
• Minimal residual disease (MRD) monitoring (detecting cancer cells even when in remission)

Important Context

According to NCCN Guidelines, the treatment landscape for HCL has evolved significantly:

For newly diagnosed patients: Purine analogs (cladribine or pentostatin), often with rituximab, remain the preferred first-line approach because they produce durable remissions in most patients.

For relapsed/refractory disease: The newer targeted therapies (BRAF inhibitors, venetoclax, BTK inhibitors) are increasingly important options, especially for patients who:

• Don't respond to standard chemotherapy
• Have early relapse (within 2 years)
• Cannot tolerate purine analogs due to infections or other complications

Questions to Ask Your Oncologist

If you have HCL or are being treated for it, consider asking:

1. "Has my HCL been tested for the BRAF V600E mutation? If so, what was the result?" (This determines if you're a candidate for BRAF inhibitors)

2. "Based on my specific situation, which of these newer options might be appropriate if my current treatment stops working?"

3. "Are there clinical trials available for any of these newer combinations?" (Clinical trials often provide access to cutting-edge treatments)

4. "How will you monitor for minimal residual disease (MRD) during and after treatment?" (MRD monitoring helps predict relapse risk)

5. "What's the plan if I develop side effects or don't respond as expected?" (Understanding backup options reduces anxiety)

The Bottom Line

The 2026 NCCN Guidelines reflect a field moving toward precision medicine—matching specific treatments to individual patient characteristics rather than using a one-size-fits-all approach. While purine analogs remain highly effective for initial treatment, the expanding toolkit of targeted therapies offers hope for patients with difficult-to-treat or relapsed disease.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

Sources:

• NCCN Guidelines for Hairy Cell Leukemia, Version 1.2026 (August 2025)
• Kreitman RJ, et al. Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation–positive hairy cell leukemia. Blood. 2023;141:996-1006.
• Tiacci E, De Carolis L, Santi A, Falini B. Venetoclax in relapsed or refractory hairy-cell leukemia. N Engl J Med. 2023;388:952-954.